A-Alpha Bio

Transforming drug development by rapidly and quantitatively measuring the affinities of millions of protein-protein interactions - we're hiring!

[A-Alpha Bio @AAlphaBio]

Check out our new AlphaBind preprint demonstrating our industry-leading antibody optimization model!

Also excited to share that we have measured our BILLIONTH protein-protein interaction, providing the crucial training data to predict protein binding.

https://t.co/rKwyCEcE32

[David Younger @DavidAYounger]

Excited to share our new paper using AlphaSeq data to enable predictive ML models for antibody engineering with our wonderful collaborators at @Google and @LumenBio

https://t.co/0JHFXUxX9c

[Christof Angermüller @cangermueller]

Excited to announce our latest paper on ML-guided design of single-domain antibodies against CoV-2; A collaboration between @GoogleDeepMind, @AAlphaBio and @LumenBio.

[Madrona @MadronaVentures]

Don't miss our first Founded & Funded of the year! @CPicardo talks w/ @AAlphabio's @DavidAYounger about #ML in #biotech, building business models around data, and when the CEO shouldn't be in the room! Full episode 👉 https://t.co/IlHmTQKTwb What advice do you have for founders?

[David Younger @DavidAYounger]

It was a pleasure speaking with @CPicardo from @MadronaVentures about @AAlphaBio and building a company at the intersection of life science and data science. Thank you for featuring A-Alpha Bio in the first Founded and Funded podcast of 2023!

[Madrona @MadronaVentures]

Applied machine/deep learning & #lifesciences are coming together to transform how we understand & improve life/health. We want to partner w/ teams focused on building wet/dry lab platforms & novel datasets to disrupt traditional drug discovery processes. https://t.co/NuZUBgk1rs

[A-Alpha Bio @AAlphaBio]

We’re thrilled to be part of the Top 40 Intelligent Applications created by @MadronaVentures, @PitchBook, and @GoldmanSachs. We'll celebrate next week at the #IA40 Summit sponsored by @Microsoft @Amazon.

[A-Alpha Bio @AAlphaBio]

Thank you to @frankvinluan at @medcitynews for featuring our latest collaboration with @bmsnews!

https://t.co/LVIzal0E74

#drugdiscovery #biotech #biopharma #proteindegradation

[A-Alpha Bio @AAlphaBio]

We are excited to announce our collaboration with Bristol Myers Squibb (@bmsnews) to discover molecular glue targets for protein degradation. Read more here: https://t.co/8v94liKpOH

[Genome Startup Day @GenomeStartup]

A special thank you to our alumni sponsors who participated in previous Genome Startup Day discussions & continue to support our events. We appreciate your contributions to making this an impactful and collaborative community.
@TwinStrandBio, @AAlphaBio, @WatchmakerGeno @seqWell

[A-Alpha Bio @AAlphaBio]

A-Alpha Bio has been selected as a finalist for the annual @geekwire Awards Health Innovation of the Year! It's a fantastic honor to be recognized as a finalist and a testament to the incredible science A-Alpha Bio is doing and our company's progress.
https://t.co/O55k84DcvM

[A-Alpha Bio @AAlphaBio]

We are very excited to announce our collaboration with @Livermore_Lab to accelerate antibody discovery for emerging COVID-19 variants by training machine learning models with binding data from AlphaSeq.

Read more below!

https://t.co/EuiAVk1R5R

[Parse Biosciences @ParseBio]

We are thrilled to share we've raised $41.5M in our Series B that will grow our team and expand our product portfolio! Thanks to Marshall Wace and @JHIAdvisors for co-leading the round. Check out the release for even more details https://t.co/pJalYFypM7 #singlecell #tech #vc

[A-Alpha Bio @AAlphaBio]

As we prepare for a virtual company-wide retreat tomorrow, we can't help but reminisce on previous in-person team events and how much fun they were...looking forward to the return of more moments like these soon!

[A-Alpha Bio @AAlphaBio]

"The partnership is the first announced by A-Alpha Bio in the cutting-edge and rapidly growing area of targeted protein degradation and leverages the AlphaSeq platform to quantitatively measure protein-protein binding..."

Read more below in case you missed our exciting news!

[SynBioBeta @SynBioBeta]

.@AAlphaBio Partners with @KymeraTx to Discover Novel Interactions for Molecular Glue Discovery https://t.co/bf5JZa3GDA

[Kymera Therapeutics @KymeraTx]

@KymeraTx is thrilled to partner with @AAlphaBio to discover and characterize novel pairs of E3 ubiquitin ligases and high-value therapeutic targets for the rational and prospective design and development of molecular glues.

[A-Alpha Bio @AAlphaBio]

https://t.co/HPAMtxFf0L (3/3)

[A-Alpha Bio @AAlphaBio]

We're delighted to share that we have partnered with @KymeraTx to take on the field of targeted protein degradation! Using our AlphaSeq assay, we'll identify novel interactions between high value undruggable targets and a library of E3 ubiquitin ligases to discover mol glues(1/3)

[A-Alpha Bio @AAlphaBio]

@KymeraTx We are very excited for this first-of-its-kind program, and we couldn’t ask for a better partner in Kymera, with their track record of innovation and deep expertise in targeted protein degradation. Follow the link below to learn more about this partnership! (2/3)

[A-Alpha Bio @AAlphaBio]

We are thrilled to announce that Padma Kodukula has joined A-Alpha Bio as Chief Business Officer! Padma will play the invaluable role of overseeing our BD strategy, with a focus on establishing and expanding key drug discovery partnerships.

Read more:
https://t.co/Ve38fxyGtg